Afebrile Pneumonia Syndrome Treatment & Management
- Author: Robert W Tolan Jr, MD; Chief Editor: Michael R Bye, MD more...
Approach Considerations
Usually, the degree of afebrile pneumonia syndrome (APS) is mild, although clinical and radiographic findings may appear out of proportion (particularly in infants with Chlamydia trachomatis infection); most infants do not require extensive diagnostic evaluation or hospitalization.
Infants who present with more severe illness may need prompt institution of empiric treatment, foregoing the risk of delay and expense of an extensive diagnostic evaluation. These infants often have viral illness, which does not respond to antibiotic therapy, but differentiating bacterial from viral illness is often difficult. Consider empiric antibiotic therapy if the potential benefits of early intervention outweigh the risks of unnecessary treatment.
Go to Pneumonia, Pediatric for more complete information on this topic.
Pharmacologic Treatment
Infants in whom the clinical picture suggests afebrile pneumonia syndrome (APS) may benefit from a 10- to 14-day course of erythromycin. Newer macrolides and azalides are also effective and may be tolerated better (particularly azithromycin).
Recent reports suggest an association between early receipt of erythromycin and the development of hypertrophic pyloric stenosis. Whether such an association will be substantiated or whether the effect will extend to clarithromycin or azithromycin is unclear. Thus, antimicrobial therapy for APS should be considered in the light of this potential adverse outcome.
Antiviral therapy is used in the treatment of cytomegalovirus (CMV), but only when unusually severe disease or immunocompromise is present. Severe CMV pneumonitis may require CMV hyperimmunoglobulin and antiviral therapy.
Although ribavirin is available for the treatment of RSV, disease sufficiently severe enough to merit treatment would not be APS and is beyond the scope of this discussion.
Deterrence and Prevention
Detection and treatment of maternal C trachomatis infection prevents vertical transmission of the pathogen.[9] Avoidance of other risk factors for APS is prudent. Institute appropriate isolation of all patients who are hospitalized.
Consultations
Consultation with specialists in pulmonary and infectious diseases may be helpful for more serious disease or in difficult cases.
Brewster DR, De Silva LM, Henry RL. Chlamydia trachomatis and respiratory disease in infants. Med J Aust. Oct 3 1981;2(7):328-30. [Medline].
Wolf DG, Greenberg D, Shemer-Avni Y, Givon-Lavi N, Bar-Ziv J, Dagan R. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. J Pediatr. Jan 2010;156(1):115-20. [Medline].
Brasfield DM, Stagno S, Whitley RJ, et al. Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: follow-up. Pediatrics. Jan 1987;79(1):76-83. [Medline].
Fasoli L, Paldanius M, Don M, et al. Simkania negevensis in community-acquired pneumonia in Italian children. Scand J Infect Dis. 2008;40(3):269-72. [Medline].
Chen CJ, Wu KG, Tang RB, Yuan HC, Soong WJ, Hwang BT. Characteristics of Chlamydia trachomatis infection in hospitalized infants with lower respiratory tract infection. J Microbiol Immunol Infect. Jun 2007;40(3):255-9. [Medline].
Beem MO, Saxon E, Tipple MA. Treatment of chlamydial pneumonia of infancy. Pediatrics. Feb 1979;63(2):198-203. [Medline].
Radkowski MA, Kranzler JK, Beem MO, et al. Chlamydia pneumonia in infants: radiography in 125 cases. AJR Am J Roentgenol. Oct 1981;137(4):703-6. [Medline].
Geis T, Schilling S, Segerer H. [A Young Infant with Afebrile Pneumonia Caused by Chlamydia Trachomatis]. Klin Padiatr. Aug 3 2006;[Medline].
Abzug MJ, Beam AC, Gyorkos EA, Levin MJ. Viral pneumonia in the first month of life. Pediatr Infect Dis J. Dec 1990;9(12):881-5. [Medline].
FDA Approves Roche (RHHBY)'s Valcyte(R) to Prevent Cytomegalovirus Disease in Pediatric Patients Who Receive Heart or Kidney Transplants. Available at http://www.biospace.com/news_story.aspx?NewsEntityId=154407. Accessed November 12, 2010.
Print
